These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 33220172)

  • 1. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
    ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
    Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis].
    Zhangbao BJZ; Zhou L; Wang L; Huang WJ; Zhao CB; Lu JH; Quan C
    Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):334-338. PubMed ID: 32074775
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
    Mariano R; Messina S; Kumar K; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2019 Oct; 2(10):e1912732. PubMed ID: 31596489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.
    Duan Z; Feng J
    J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 10. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Hyun JW; Lee HL; Park J; Kim J; Min JH; Kim BJ; Kim SW; Shin HY; Huh SY; Kim W; Seo JW; Kim KH; Kim SH; Kim HJ
    Mult Scler; 2022 May; 28(6):989-992. PubMed ID: 34865555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
    J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
    Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
    Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.